On July 15, 2021, ASTHO CEO, Michael Fraser, PhD, issued a statement support for U.S. Surgeon General Vivek Murthy’s new advisory "Confronting Misinformation: The U.S. Surgeon General’s Advisory ...
On July 13, 2021, ASTHO issued a statement of support for President Joe Biden’s nomination of Rahul Gupta, MD, MPH, MBA, FACP, to serve as the Director of the Office of National Drug Control Policy.
ASTHO issued a statement of concern for public health and healthcare workers on June 25, 2021, following the publication of a CDC MMWR Early Release, that details the devastating effects of the ...
On May 13, 2021, ASTHO CEO Michael Fraser issued a strong statement of support for the Biden administration's American Rescue Plan Act of 2021, which includes a large investment in public heath.
On April 29, 2021, ASTHO and its members announced support for FDA actions in advancing two tobacco product standards rulemaking processes to remove menthol as a characterizing flavor in cigarettes ...
On Oct. 22, 2020, in preparation for National Vote Early Day, ASTHO joined voter education groups and local public health agencies to remind voters of steps they can take to ensure they stay healthy ...
On April 12, 2023, ASTHO released a statement applauding the Office of National Drug Control Policy’s announcement designating fentanyl adulterated or associated with xylazine as an emerging drug ...
On March 23, 2023, ASTHO President Anne Zink testified before the U.S. House of Representatives Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies.
ASTHO Applauds Administration's Commitment to Combat the Opioid Epidemic ARLINGTON, VA—Michael Fraser, executive director of ASTHO, issued the following response to HHS Secretary Tom Price’s ...
On Jan. 30, 2023, ASTHO released a statement commending the FDA on a new proposal to conduct individual risk assessments for blood donors, a policy that reflects the best available science while not ...